Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P432: VALIDATION OF LIMIT OF Q...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL

P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL

Bibliographic Details
Main Authors: Jesse Tettero, Raffaele Palmieri, Lok Lam Ngai, Costa Bachas, Valentina Arena, Dimitri Breems, Thomas Fischer, Bjorn Tore Gjertsen, Laimonas Griškevičius, Gunnar Juliusson, Johan Maertens, Markus Manz, Luca Maurillo, Thomas Pabst, Jakob Passweg, Alfonso Piciocchi, Kimmo Porkka, Bob Löwenberg, Adriano Venditti, Gert Ossenkoppele, Francesco Buccisano, Jacqueline Cloos
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000968636.18625.e3
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000968636.18625.e3

Similar Items

  • Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
    by: Jesse M. Tettero, et al.
    Published: (2023-04-01)
  • The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed
    by: Katerina Bakunina, et al.
    Published: (2022-02-01)
  • Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG
    by: Roland B. Walter, et al.
    Published: (2015-10-01)
  • Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial
    by: Niek G. van der Maas, et al.
    Published: (2024-03-01)
  • Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis
    by: Jesse M. Tettero, et al.
    Published: (2022-10-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs